The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10480 malaria professionals are enjoying the free benefits of MalariaWorld today

artemisinin derivatives

Effect of mild medical hypothermia on in vitro growth of Plasmodium falciparum and the activity of anti-malarial drugs

March 16, 2016 - 17:50 -- Open Access
Author(s): 
Khalid Rehman, Ulrich Sauerzopf, Luzia Veletzky, Felix Lötsch, Mirjam Groger and Michael Ramharter
Reference: 
Malaria Journal 2016 15:162, 15 March 2016

This preclinical evaluation demonstrates that mild medical hypothermia inhibits in vitro growth of P. falciparum and enhances the pharmacodynamic activity of artemisinin derivatives.

Medical Treatment: 

NOT Open Access | Highly potent artemisinin-derived dimers and trimers: Synthesis and evaluation of their antimalarial, antileukemia and antiviral activities

September 3, 2015 - 14:30 -- NOT Open Access
Author(s): 
Christoph Reiter, Tony Fröhlich, Svetlana B. Tsogoeva, et al.
Reference: 
Bioorganic & Medicinal Chemistry, Volume 23, Issue 17, 1 September 2015, Pages 5452–5458

New pharmaceutically active compounds can be obtained by modification of existing drugs to access more effective agents in the wake of drug resistance amongst others.

Medical Treatment: 

NOT Open Access | Artemisinin-Resistant Plasmodium falciparum Parasites Exhibit Altered Patterns of Development in Infected Erythrocytes

May 18, 2015 - 14:31 -- NOT Open Access
Author(s): 
Amanda Hott, Debora Casandra, Kansas N. Sparks, Lindsay C. Morton, Geocel-Grace Castanares, Amanda Rutter, and Dennis E. Kyle
Reference: 
Antimicrob. Agents Chemother. June 2015 vol. 59 no. 6 3156-3167

Artemisinin derivatives are used in combination with other antimalarial drugs for treatment of multidrug-resistant malaria worldwide

Medical Treatment: 

NOT Open Access | Treatment of Murine Cerebral Malaria by Artemisone in Combination with Conventional Antimalarial Drugs: Antiplasmodial Effects and Immune Responses

July 16, 2014 - 07:55 -- NOT Open Access
Author(s): 
W. Armand Guiguemde, Nicholas H. Hunt, Jintao Guo, Annael Marciano, Richard K. Haynes, Julie Clark, R. Kiplin Guy, and Jacob Golenser
Reference: 
Antimicrob. Agents Chemother. August 2014 vol. 58 no. 8 4745-4754

The decreasing effectiveness of antimalarial therapy due to drug resistance necessitates constant efforts to develop new drugs.

Medical Treatment: 

Ex vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy change

June 10, 2014 - 15:14 -- Open Access
Author(s): 
Tinto H, Bonkian LN, D'Alessandro U, et al.
Reference: 
Malaria Journal 2014, 13 :207 (31 May 2014)

Artemisinin derivatives are still very efficacious in Burkina Faso and DHA-PPQ seems a valuable alternative ACT.

Medical Treatment: 

Optimal sampling designs for estimation of Plasmodium falciparum clearance rates in patients treated with artemisinin derivatives

November 21, 2013 - 09:05 -- Open Access
Author(s): 
Flegg JA, Guérin PJ, Stepniewska K, et al.
Reference: 
Malaria Journal 2013, 12 :411 (13 November 2013)
MalariaWorld

This study has revealed important insights on sampling schedules for accurate and reliable estimation of Plasmodium falciparum half-life following treatment with an artemisinin derivative (alone or in combination with a partner drug).

Medical Treatment: 

NOT Open Access | Comparative Ex Vivo Activity of Novel Endoperoxides in Multidrug-Resistant Plasmodium falciparum and P. vivax

September 13, 2012 - 13:16 -- Kabogo Ndegwa
Author(s): 
Jutta Marfurt, Ferryanto Chalfein, Ric N. Price, et al.
Reference: 
Antimicrob. Agents Chemother. October 2012 vol. 56 no. 10 5258-5263

 

MalariaWorldThe declining efficacy of artemisinin derivatives against Plasmodium falciparum highlights the urgent need to identify alternative highly potent compounds for the treatment of malaria.

Medical Condition: 

Arterolane, a New Synthetic Trioxolane for Treatment of Uncomplicated Plasmodium falciparum Malaria: A Phase II, Multicenter, Randomized, Dose-Finding Clinical Trial

August 10, 2010 - 09:38 -- Kabogo Ndegwa
Tags: 
Author(s): 
N Valecha, S Looareesuwan, A Martensson, SM Abdulla, S Krudsood, N Tangpukdee, S Mohanty, SK Mishra, PK Tyagi, SK Sharma, J Moehrle, A Gautam, A Roy, JK Paliwal, M Kothari, N Saha, AP Dash, A örkman
Reference: 
Clinical Infectious Diseases 2010;51:000–000

Arterolane at daily doses of 100 and 200 mg is a rapidly acting, effective, and safe synthetic antimalarial drug, which may potentially represent an alternative to artemisinin derivatives in antimalarial combination therapy.

Medical Condition: 
Medical Treatment: 
Subscribe to RSS - artemisinin derivatives